Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



3 Reasons Sanofi's Stock Could Rise

After a rocky second quarter, biopharma stocks have rallied in a big way heading toward the end of the year. Gilead Sciences, for example, has shot up 41.5% year to date, with most of this upward movement coming in recent weeks. 

Even so, Sanofi (NYSE: SNY  )  and some other large-cap pharma stocks have largely failed to participate in this broad-based rally. To illustrate this point, the iShares Nasdaq Biotechnology Index (NASDAQ: IBB  ) has now risen by close to 22% in 2014, yet Sanofi's shares have posted a mere 5.8% gain thus far.

SNY Chart

SNY data by YCharts.

Sanofi's anemic gains, in comparison to its peers, are likely due to the company reorganizing following a bout with the so-called patent cliff. With most of these patent issues firmly in the past, I believe there are three reasons why Sanofi is now set to return to growth, making it a stock to watch.

Reason No. 1
Sanofi's late-stage pipeline is expected to generate two additional major drug approvals (Toujeo and Lemtrada) within the next 12 months in the U.S. Earlier this month, the Food and Drug Administration approved Cerdelga for the treatment of Gaucher disease type 1, with a commercial launch expected as soon as September. So if all goes as planned on the regulatory front, Sanofi should see a nice bump in top-line growth next year, with experts projecting a forward price-to-earnings ratio somewhere in the low teens. 

Moreover, Sanofi and partner Regeneron (NASDAQ: REGN  ) recently released strong late-stage top-line results for alirocumab as a potential treatment for hypercholesterolemia; they subsequently announced that regulatory filings in the U.S. and European Union should be completed before year's end. The two companies have set up a thematic conference call to discuss alirocumab with investors on Sept. 2. 

All told, Sanofi appears to be on the fast track to return to growth due, in large part, to a promising clinical pipeline and research collaborations.   

Reason No. 2
Sanofi's Genzyme unit is back to posting double-digit growth as a result of its Fabry disease therapy, Fabrazyme, regaining market share in the U.S. and the highly successful launch of Aubagio for multiple sclerosis last year. Taken together, these two events helped Genzyme sales leap by 29.1%, year over year, in the second quarter. 

Looking ahead, the potential entry of Amicus Therapeutics'  (NASDAQ: FOLD  ) competing Fabry disease treatment could cut into Fabrazyme's growing sales down the line. However, Amicus' oral therapy isn't expected to be used as a broad-based treatment, suggesting that its competitive impact might be limited.

Reason No. 3
In the first half of 2014, Sanofi saw a 33% year-over-year increase in free cash flow. Although the company has not rewarded shareholders by significantly upping either the dividend or share repurchases lately, this notable increase in free cash flow should translate into stable dividend payments and stock buybacks going forward. 

Some of Sanofi's peers have recently suspended repurchasing shares in light of their own patent issues, while other growing biotechs with even stronger cash positions have yet to consider offering a dividend.

So as Sanofi continues to move past the patent cliff and transitions into new products, investors looking for a stable source of income could find this name quite attractive.

Foolish wrap-up
Sanofi's growth strategy is unfolding nicely with the approval of Cerdelga and the monstrous growth of its Genzyme subsidiary. That said, the approval of its long-anticipated multiple sclerosis drug Lemtrada is far from a shoe-in, given that it was rejected by the FDA last year and this resubmission is based solely on hope that a new analysis of old data will somehow sway regulators this time around. Regardless of Lemtrada's ultimate regulatory fate, I believe Sanofi has enough irons in the fire to make it a stock worth putting on your watchlist.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3083459, ~/Articles/ArticleHandler.aspx, 8/31/2015 1:08:40 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated 2 days ago Sponsored by:
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 1.21 0.06%
NASD 4,828.33 15.62 0.32%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes